Use of atomoxetine in a patient with fibromyalgia syndrome and attention-deficit hyperactivity disorder

Yakov Vorobeychik, Martin A. Acquadro

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Background: We describe a 65-year-old patient with adult attention deficit hyperactivity disorder [ADHD], poorly controlled by adderall XR, and generalized pain from fibromyalgia syndrome [FMS]. The patient's pain did not respond to amitriyptyline, lidoderm patch, percocet, diazepam, metaxalone, ibuprofen, or gabapentin. Findings: Her pain related to FMS responded dramatically to atomoxetine, a selective norepinephrine reuptake inhibitor approved by the Food and Drug Administration for ADHD treatment, which was substituted for adderall XR in this patient. The patient reported a 60 percent pain reduction and marked improvement of her functional status, as well as improvement regarding her ADHD. Conclusions: We suggest that atomoxetine might be a useful adjunct in the treatment of FMS, and possibly neuropathic pain conditions.

Original languageEnglish (US)
Pages (from-to)189-192
Number of pages4
JournalJournal of Musculoskeletal Pain
Volume16
Issue number3
DOIs
StatePublished - Jul 16 2008

Fingerprint

Fibromyalgia
Attention Deficit Disorder with Hyperactivity
Pain
Ibuprofen
Neuralgia
United States Food and Drug Administration
Diazepam
Norepinephrine
Atomoxetine Hydrochloride
Therapeutics
SLI381

All Science Journal Classification (ASJC) codes

  • Rheumatology

Cite this

@article{03fcdd9a3039434fb190c6b20b4bb60b,
title = "Use of atomoxetine in a patient with fibromyalgia syndrome and attention-deficit hyperactivity disorder",
abstract = "Background: We describe a 65-year-old patient with adult attention deficit hyperactivity disorder [ADHD], poorly controlled by adderall XR, and generalized pain from fibromyalgia syndrome [FMS]. The patient's pain did not respond to amitriyptyline, lidoderm patch, percocet, diazepam, metaxalone, ibuprofen, or gabapentin. Findings: Her pain related to FMS responded dramatically to atomoxetine, a selective norepinephrine reuptake inhibitor approved by the Food and Drug Administration for ADHD treatment, which was substituted for adderall XR in this patient. The patient reported a 60 percent pain reduction and marked improvement of her functional status, as well as improvement regarding her ADHD. Conclusions: We suggest that atomoxetine might be a useful adjunct in the treatment of FMS, and possibly neuropathic pain conditions.",
author = "Yakov Vorobeychik and Acquadro, {Martin A.}",
year = "2008",
month = "7",
day = "16",
doi = "10.1080/10582450802161960",
language = "English (US)",
volume = "16",
pages = "189--192",
journal = "Journal of Musculoskeletal Pain",
issn = "1058-2452",
publisher = "Informa Healthcare",
number = "3",

}

Use of atomoxetine in a patient with fibromyalgia syndrome and attention-deficit hyperactivity disorder. / Vorobeychik, Yakov; Acquadro, Martin A.

In: Journal of Musculoskeletal Pain, Vol. 16, No. 3, 16.07.2008, p. 189-192.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Use of atomoxetine in a patient with fibromyalgia syndrome and attention-deficit hyperactivity disorder

AU - Vorobeychik, Yakov

AU - Acquadro, Martin A.

PY - 2008/7/16

Y1 - 2008/7/16

N2 - Background: We describe a 65-year-old patient with adult attention deficit hyperactivity disorder [ADHD], poorly controlled by adderall XR, and generalized pain from fibromyalgia syndrome [FMS]. The patient's pain did not respond to amitriyptyline, lidoderm patch, percocet, diazepam, metaxalone, ibuprofen, or gabapentin. Findings: Her pain related to FMS responded dramatically to atomoxetine, a selective norepinephrine reuptake inhibitor approved by the Food and Drug Administration for ADHD treatment, which was substituted for adderall XR in this patient. The patient reported a 60 percent pain reduction and marked improvement of her functional status, as well as improvement regarding her ADHD. Conclusions: We suggest that atomoxetine might be a useful adjunct in the treatment of FMS, and possibly neuropathic pain conditions.

AB - Background: We describe a 65-year-old patient with adult attention deficit hyperactivity disorder [ADHD], poorly controlled by adderall XR, and generalized pain from fibromyalgia syndrome [FMS]. The patient's pain did not respond to amitriyptyline, lidoderm patch, percocet, diazepam, metaxalone, ibuprofen, or gabapentin. Findings: Her pain related to FMS responded dramatically to atomoxetine, a selective norepinephrine reuptake inhibitor approved by the Food and Drug Administration for ADHD treatment, which was substituted for adderall XR in this patient. The patient reported a 60 percent pain reduction and marked improvement of her functional status, as well as improvement regarding her ADHD. Conclusions: We suggest that atomoxetine might be a useful adjunct in the treatment of FMS, and possibly neuropathic pain conditions.

UR - http://www.scopus.com/inward/record.url?scp=67650308245&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67650308245&partnerID=8YFLogxK

U2 - 10.1080/10582450802161960

DO - 10.1080/10582450802161960

M3 - Article

AN - SCOPUS:67650308245

VL - 16

SP - 189

EP - 192

JO - Journal of Musculoskeletal Pain

JF - Journal of Musculoskeletal Pain

SN - 1058-2452

IS - 3

ER -